Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
James N. Kochenderfer, M.D., an investigator
in the Experimental Transplantation and Immunology Branch of the NCI, is
currently conducting a Phase 1 clinical trial of the product candidate
in patients with B-cell malignancies under an existing
"The expansion of our CAR-T pipeline to include a fully human anti-CD19 chimeric antigen receptor supports our effort to maximize the potential benefit of CAR-T therapies for patients with advanced B-cell malignancies. As the field of T-cell therapy continues its rapid advancement, we remain committed to collaborating with the world's most distinguished institutions and accessing the most significant enabling technologies to pioneer the next generation of T-cell therapies," said
Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer.
About
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
advance and the success of a fully human anti-CD19 chimeric antigen
receptor-based product candidate directed against B-cell malignancies
and the ability and willingness of the NCI to continue research and
development activities pursuant to the CRADA. Various factors may cause
differences between Kite's expectations and actual results as discussed
in greater detail in Kite's filings with the
Комментарии